{
    "clinical_study": {
        "@rank": "80470", 
        "arm_group": [
            {
                "arm_group_label": "Early treatment with mesenchymal stem cells", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Delayed treatment with mesenchymal stem cells", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the safety and efficacy of autologous mesenchymal\n      stromal cells as treatment for Multiple Sclerosis."
        }, 
        "brief_title": "Mesenchymal Stem Cells for Multiple Sclerosis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of MS\n\n             a. Relapsing remitting MS (RRMS) not responding to at least a year of attempted\n             therapy with one or more of the approved therapies (beta-interferon, glatiramer\n             acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by one or more of the\n             following: i. \u22651 clinically documented relapse in past 12 months ii. \u22652 clinically\n             documented relapses in last 24 months iii. \u22651 GEL at MRI performed within the last 12\n             months\n\n             b. Secondary progressive MS (SPMS) not responding to at least a year of attempted\n             therapy with one or more of the approved therapies (beta-interferon, glatiramer\n             acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by both: i. an increase\n             of \u22651 EDSS point (if at randomization EDSS \u2264 5.0) or 0.5 EDSS point (if at\n             randomization EDSS \u2265 5.5) in the last 12 months ii. \u22651 clinically documented relapse\n             or \u2265 1 GEL at MRI within the last twelve months.\n\n             c. Primary progressive MS (PPMS) patients with all the following features: i.  an\n             increase of \u22651 EDSS point (if at randomization EDSS \u2264 5.0) or 0.5 EDSS point (if at\n             randomization EDSS \u22655.5), in the last twelve months ii. \u2265 1 GEL at MRI performed\n             within the last 12 months iii. positive cerebrospinal fluid (CSF) (oligoclonal\n             banding)\n\n          2. Age 18 to 50 years\n\n          3. Disease duration 2 to 10 years (included)\n\n          4. EDSS 3.0 to 6.5\n\n        Exclusion Criteria:\n\n          1. RRMS not fulfilling inclusion criteria\n\n          2. SPMS not fulfilling inclusion criteria\n\n          3. PPMS not fulfilling inclusion criteria\n\n          4. Any active or chronic infection including infection with HIV1-2 or chronic Hepatitis\n             B or Hepatitis C\n\n          5. Treatment with any immunosuppressive therapy, including natalizumab and fingolimod,\n             within the 3 months prior to randomization\n\n          6. Treatment with interferon-beta or glatiramer acetate within the 30 days prior to\n             randomization\n\n          7. Treatment with corticosteroids within the 30 days prior to randomization\n\n          8. Relapse occurred during the 60 days prior to randomization\n\n          9. Previous history of a malignancy other than basal cell carcinoma of the skin or\n             carcinoma in situ that has been in remission for more than one year\n\n         10. Severely limited life expectancy by another co-morbid illness\n\n         11. History of previous diagnosis of myelodysplasia or previous hematologic disease or\n             current clinically relevant abnormalities of white blood cell counts\n\n         12. Pregnancy or risk or pregnancy (this includes patients that are unwilling to practice\n             active contraception during the duration of the study)\n\n         13. eGFR < 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI\n             examination.\n\n         14. Inability to give written informed consent in accordance with research ethics board\n             guidelines"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730547", 
            "org_study_id": "MSC-MS"
        }, 
        "intervention": {
            "arm_group_label": [
                "Early treatment with mesenchymal stem cells", 
                "Delayed treatment with mesenchymal stem cells"
            ], 
            "intervention_name": "Autologous mesenchymal stem cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Mesenchymal stem cells", 
            "Multiple Sclerosis", 
            "Autoimmune diseases"
        ], 
        "lastchanged_date": "February 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden", 
                    "zip": "171 76"
                }, 
                "name": "Karolinska Institute, Karolinska University Hospital Solna"
            }, 
            "investigator": [
                {
                    "last_name": "Lou Brundin, MD. Professor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ellen Iacobaeus, MD. PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katarina Le Blanc, MD. Professor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis", 
        "overall_contact": {
            "email": "lou.brundin@karolinska.se", 
            "last_name": "Lou Brundin, MD.Professor", 
            "phone": "+46 7074848505", 
            "phone_ext": "+46"
        }, 
        "overall_contact_backup": {
            "email": "ellen.iacobaeus@karolinska.se", 
            "last_name": "Ellen Iacobaeus, MD.PhD", 
            "phone": "+46 707433644", 
            "phone_ext": "+46"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: The National Board of Health and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to assess the safety of IV therapy with autologous MSCs in MS. Number of participants with adverse events will be documented at week 0,4,8,12,16,20,24,28,32,36,40,44,48 post treatment. Co-primary objective of the study is to evaluate the activity of autologous MSCS in MS patients, in terms of reduction as compared to placebo in the total number of contrast-enhancing lesions (GEL) at MRI acquired on conventional 1,5 T MRI scans over 24 weeks.", 
            "measure": "To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730547"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Ellen Iacobaeus", 
            "investigator_title": "MD.PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska Institutet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}